14.7 Sexually Transmitted Infections and Partner Care

Key Takeaways

  • Choose STI samples using the affected anatomy, exposure sites and symptoms. NAAT detects infection and gonococcal culture helps determine susceptibility.

  • Use the Irish infection-specific treatment, partner and follow-up rules. Escalate complicated disease or pregnancy when indicated.

  • Know when to suspect herpes or syphilis in genital ulceration, and arrange HIV PEP assessment without delay after a significant recent exposure.

Last updated: November 2026

Assess symptoms and choose specimens

Start in private and ask permission to take a sexual history. Establish symptoms and onset, partners and contact sites, barrier use, prior infections or treatment, pregnancy possibility, travel and vaccinations. Ask about coercion or assault when appropriate and explain confidentiality and its limits. Select tests using the person's anatomy, sexual exposures and symptoms. For example, urinalysis or a midstream urine culture for a suspected urinary infection has a different purpose from a first-void urine specimen for a sexually transmitted infection (STI).

Urethral discharge with dysuria suggests urethritis. Cervicitis may cause discharge, postcoital or intermenstrual bleeding and can be asymptomatic. Perform relevant genital examination with consent and assess for ulcers, warts, proctitis, epididymo-orchitis and pelvic inflammatory disease (PID). A person with acute severe unilateral scrotal pain needs urgent assessment for torsion. A person with lower abdominal pain and bleeding needs consideration of pregnancy and ectopic pregnancy. Severe proctitis with rectal pain, discharge or bleeding calls for prompt referral, including consideration of lymphogranuloma venereum.

Use nucleic acid amplification testing (NAAT) for chlamydia and gonorrhoea. First-void urine is useful for penile urethral infection and a self- or clinician-collected vulvovaginal swab is appropriate for vaginal sampling. Arrange pharyngeal and rectal sampling when indicated by the HSE guidance, including recommended three-site testing in sexually active gay, bisexual and other men who have sex with men. For gonorrhoea, HSE v3.0 also recommends pharyngeal and rectal testing for sexually active transgender women and sex workers. Pharyngeal testing is indicated in diagnosed urogenital infection and in sexual contacts. Use current anatomy, sites of exposure and applicable guidance to select samples. Seek specific advice after gender-affirming surgery when anatomy or sampling requirements are uncertain. Ask the laboratory about assay and swab requirements rather than using the same kit for every specimen. Offer HIV and syphilis testing and assess hepatitis B and C testing and vaccination needs using exposure and the clinical context. A recent exposure may require repeat testing after a window period. Arrange follow-up and tell the patient how results will be provided.

Worked decision. A patient with purulent penile discharge after recent sex has chlamydia and gonorrhoea NAAT performed. When gonorrhoea is detected, arrange a separate sample for culture before antibiotics where feasible. The NAAT identifies the infection. Culture can guide surveillance and antibiotic susceptibility. Do not wait for antimicrobial susceptibility results to start indicated first-line treatment.

HSE primary care STI consultation · Gonorrhoea v3.0.

Treat chlamydia and gonorrhoea and reduce reinfection

InfectionIrish community treatment decisionPartners and follow-up
Uncomplicated chlamydiaHSE first choice is doxycycline 100 mg orally every 12 hours for 7 days. Doxycycline in this regimen is contraindicated in pregnancy. Seek specialist advice in pregnancy or breastfeeding. HSE reserves azithromycin for situations where doxycycline is contraindicated and uses a three-day course when azithromycin is indicated. PID and suspected invasive rectal infection use separate pathways.Notify partners from the preceding 6 months. A contact tested within 2 weeks of last exposure may test falsely negative. HSE recommends empirical treatment for contacts in that window. Test of cure is selective, including rectal infection, pregnancy and people with an intrauterine device, at least 3 weeks after completing treatment. Avoid sexual contact until treatment is completed or a required test of cure is negative.
Uncomplicated anogenital or pharyngeal gonorrhoeaHSE v3.0 uses ceftriaxone 1 g deep IM once when suitable. Take culture from positive sites before treatment where feasible. Refer or seek specialist advice when ceftriaxone cannot be used, including relevant allergy. Seek advice in pregnancy or breastfeeding. The HSE advises against empirical cefixime, azithromycin or ciprofloxacin.Notify partners in the previous 2 weeks for symptomatic penile urethral infection, or the most recent partner if earlier. For other sites or asymptomatic infection, the interval is 3 months. If susceptibility is unknown, infection is pharyngeal, symptoms persist, treatment was other than ceftriaxone, or the patient is pregnant, arrange test of cure at 2–3 weeks after treatment. Review ongoing symptoms sooner. Avoid sex until a required test of cure is negative, or for 2 weeks if it is unnecessary.

A susceptible anogenital isolate treated with ceftriaxone 1 g generally does not need a gonorrhoea test of cure. A positive result or persistent symptoms may indicate reinfection or possible treatment failure. Clarify adherence and exposure, and seek specialist and laboratory guidance. Offer partner notification support. The lookback period for identifying partners is distinct from the interval used to interpret their results or decide on empirical treatment. Test gonorrhoea contacts at genital and pharyngeal sites, with rectal testing as indicated. In the first 2 weeks after exposure, HSE allows epidemiological treatment for some contacts, based on factors such as pregnancy or barriers to follow-up. For other contacts with an early negative result, repeat testing after the two-week window. For contacts presenting beyond the window, await their results before treating on this basis. Offer testing for additional STIs. Follow Irish notification requirements for notifiable infections even when a laboratory initiates the process.

Chlamydia v2.0 · Gonorrhoea v3.0 · HPSC notification.

Genital ulcers, warts and HIV prevention

A painless chancre can suggest primary syphilis, but ulcer appearance alone is unreliable. Secondary syphilis can present with a generalised rash and systemic features. Offer syphilis serology when indicated and seek genitourinary medicine or infectious disease advice about positive results. Treponemal screening can stay reactive after treatment. Previous results, further serology, exposure and symptoms help distinguish treated infection from current infection. Parenteral penicillin is first line, with the regimen selected by stage and circumstances. Refer patients with new diagnoses for staging, treatment and partner notification. Positive antenatal serology needs prompt specialist review. Neurological, ocular or otic features warrant urgent assessment.

Grouped vesicles or painful ulcers can suggest genital herpes. Take a lesion NAAT swab when possible and start oral antiviral treatment promptly if the clinical suspicion is reasonable. One HSE option for a first episode is valaciclovir 500 mg every 12 hours for five days, adjusted where required. New lesions during treatment or incomplete healing merit review and possibly a longer course or specialist referral. Acute urinary retention, meningism or severe systemic symptoms warrant urgent assessment. Discuss symptom-free viral shedding and avoidance of sexual contact with active lesions. For a first episode in pregnancy, start appropriate treatment and involve sexual health and obstetrics, especially in the third trimester.

Typical anogenital warts are usually associated with low-risk HPV types 6 and 11. Small-volume disease can regress, and external lesions can be treated with an appropriate topical regimen or cryotherapy depending on appearance and site. Use specialist advice for internal, atypical, ulcerated or otherwise suspicious lesions, and check pregnancy before prescribing. Offer other STI tests. HPV vaccination and cervical screening have their own eligibility rules and do not remove established warts.

Time-dependent prevention. For a possible significant HIV exposure, assess urgently rather than waiting for a screening test to become positive. When indicated, HIV post-exposure prophylaxis (PEP) starts as soon as possible and within 72 hours, with a 28-day course. Refer to a sexual health or infectious disease service, or an emergency department if timely access is otherwise unavailable. Follow separate acute sexual assault and occupational pathways where indicated. For ongoing acquisition risk, discuss pre-exposure prophylaxis (PrEP) and baseline HIV testing with an appropriate service. Discuss barrier use and relevant hepatitis B and HPV vaccination. PrEP protects against HIV and does not treat or prevent other STIs.

Syphilis v2.0 · Genital herpes v2.0 · Warts v2.0 · HSE HIV PEP · HSE PrEP guidance.

Test Your Knowledge

A 26-year-old with penile urethral discharge has a positive gonorrhoea NAAT. Chlamydia testing is negative, there are no signs of complicated disease and there is no relevant allergy. A culture sample can be collected today, but susceptibility is unknown. What plan follows HSE community guidance?

A

Collect culture before treatment if feasible, give ceftriaxone 1 g deep IM once, and arrange test of cure because susceptibility is unknown

B

Repeat the NAAT before treating and use oral ciprofloxacin while awaiting susceptibility

C

Give a single dose of oral azithromycin and arrange no further testing

D

Take culture and defer any treatment until susceptibility testing is complete

Test Your Knowledge

A patient presents 44 hours after a sexual exposure that a clinician considers a substantial HIV acquisition risk. The patient is not taking PrEP, the local sexual health service is closed and prompt ED assessment is available. What is the next step?

A

Wait until the end of the HIV test window before referring

B

Arrange urgent PEP assessment today and start PEP promptly if indicated

C

Prescribe ongoing PrEP and postpone assessment for the recent exposure

D

Repeat testing in three months without addressing the current time-sensitive risk

Sections you finish are checked off in the contents.